


## hDHODH-IN-11

<b>Cat. No.:</b>	HY-151560
<b>CAS No.:</b>	2396653-34-0
<b>Molecular Formula:</b>	C <sub>24</sub> H <sub>23</sub> N <sub>3</sub> O <sub>3</sub>
<b>Molecular Weight:</b>	401.46
<b>Target:</b>	Dihydroorotate Dehydrogenase
<b>Pathway:</b>	Metabolic Enzyme/Protease
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	hDHODH-IN-11 is a potent human dihydroorotate dehydrogenase (hDHODH) inhibitor with an IC <sub>50</sub> value of 7.2 nM. hDHODH-IN-11 has low cytotoxicity. hDHODH-IN-11 can be used in research of acute myeloid leukemia (AML) <sup>[1]</sup> .									
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : 7.2 nM (hDHODH) <sup>[1]</sup>									
<b>In Vitro</b>	<p>hDHODH-IN-11 (0.1 and 1 μM; 72 h; THP1 and U937 cells) has low cytotoxicity, pro-apoptotic and pro-differentiating abilities<sup>[1]</sup>.</p> <p>hDHODH-IN-11 (0.1 μM; 72 h; THP1 and MV4-11 cells) with <a href="#">Dipyridamole</a> (HY-B0312) results in synergistic effect and demonstrates a good pro-apoptotic activity<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>									
<b>In Vivo</b>	<p>hDHODH-IN-11 (20 mg/kg; i.p.; daily, for 13 d; Balb/c mice with AML xenografts) reduces the leukemic burden and tumor weight<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>Balb/c mice with AML xenografts<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>20 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection; daily, for 13 days</td> </tr> <tr> <td>Result:</td> <td>Reduced the leukemic burden and tumor weight.</td> </tr> </table>		Animal Model:	Balb/c mice with AML xenografts <sup>[1]</sup>	Dosage:	20 mg/kg	Administration:	Intraperitoneal injection; daily, for 13 days	Result:	Reduced the leukemic burden and tumor weight.
Animal Model:	Balb/c mice with AML xenografts <sup>[1]</sup>									
Dosage:	20 mg/kg									
Administration:	Intraperitoneal injection; daily, for 13 days									
Result:	Reduced the leukemic burden and tumor weight.									

### REFERENCES

[1]. Sainas S, et, al. Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold: SAR of the Aryloxyaryl Moiety. J Med Chem. 2022 Oct 13;65(19):12701-12724.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA